Clinically significant cardiovascular effects and fatalities have been reported with excessive use of inhaled sympathomimetic drugs. Patients using Trelegy Ellipta should not use another medicine ...

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market. Top-line ...

Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...

With prices finalized for the first 10 Medicare Part D drugs selected for the initial ... for the first time with their ...

You can also refer to this in-depth Trelegy Ellipta for a comprehensive look at this drug and its other uses. There are four stages of COPD, ranging from mild to severe. Your doctor will determine ...